tiprankstipranks
Ercros SA (ES:ECR)
BME:ECR
Want to see ES:ECR full AI Analyst Report?

Ercros SA (ECR) Price & Analysis

5 Followers

ECR Stock Chart & Stats

€3.43
€0.00(0.00%)
At close: 4:00 PM EST
€3.43
€0.00(0.00%)

Bulls Say, Bears Say

Bulls Say
Cash Generation ResiliencePositive operating and free cash flow in 2025 demonstrates the company's ability to convert operations into cash even amid earnings weakness. That durable cash generation supports working capital, modest capex, and debt servicing over the next several quarters, providing a financial buffer against cyclical downturns.
Moderate Leverage CushionAlthough leverage has risen, the balance sheet still shows debt beneath equity in 2025, offering a structural cushion versus highly leveraged peers. This lower absolute leverage gives management more flexibility to manage refinancing, absorb shocks, and pursue operational improvements without immediate solvency pressure.
Diversified Chemical Portfolio And End MarketsA broad product mix across chlor-alkali, intermediates and specialty products serving multiple industrial end markets reduces single-market dependency. Structural demand from water treatment, detergents, pulp & paper and pharmaceuticals supports more stable volumes and helps smooth cycles over a 2–6 month horizon as customers have recurring industrial needs.
Bears Say
Sharply Deteriorating ProfitabilityThe shift from multi-year profitability to sustained losses undermines operating leverage and depletes retained earnings, damaging long-term competitiveness. Persisting negative operating profit reduces reinvestment capacity, weakens margins and risks permanent customer or cost-structure erosion unless margins are restored.
Rising Leverage And Declining EquityIncreasing debt-to-equity and falling shareholder equity materially reduce financial flexibility and increase vulnerability to interest rate or demand shocks. Continued equity erosion limits ability to raise capital on favorable terms and raises refinancing risk if cash flows falter, making recovery more difficult.
Volatile Cash Flow PerformanceMarked swings in free cash flow signal inconsistent working capital or margin dynamics and weaken predictability of funds for capex and debt service. This volatility increases financing risk, complicates multi-period planning, and suggests earnings quality issues that could hinder durable operational improvement.

Ercros SA News

ECR FAQ

What was Ercros SA’s price range in the past 12 months?
Ercros SA lowest stock price was €2.23 and its highest was €3.48 in the past 12 months.
    What is Ercros SA’s market cap?
    Ercros SA’s market cap is €316.83M.
      When is Ercros SA’s upcoming earnings report date?
      Ercros SA’s upcoming earnings report date is Jul 29, 2026 which is in 56 days.
        How were Ercros SA’s earnings last quarter?
        Ercros SA released its earnings results on May 20, 2026. The company reported -€0.266 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.266.
          Is Ercros SA overvalued?
          According to Wall Street analysts Ercros SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Ercros SA pay dividends?
            Ercros SA pays a Annually dividend of €0.096 which represents an annual dividend yield of 2.27%. See more information on Ercros SA dividends here
              What is Ercros SA’s EPS estimate?
              Ercros SA’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Ercros SA have?
              Ercros SA has 91,436,195 shares outstanding.
                What happened to Ercros SA’s price movement after its last earnings report?
                Ercros SA reported an EPS of -€0.266 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.146%.
                  Which hedge fund is a major shareholder of Ercros SA?
                  Currently, no hedge funds are holding shares in ES:ECR
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    Ercros SA

                    Ercros, S.A. manufactures and sells basic chemicals, intermediate chemicals, and pharmaceuticals in Spain. It operates through three segments: Chlorine Derivatives, Intermediate Chemicals, and Pharmacy. The Chlorine Derivatives segment produces ammonia, bioplastics, caustic potash and soda, chlorine, chloroisocyanurates, dicalcium phosphate, dichloroethane, hydrochloric acid, hydrogen peroxide, potassium carbonate, PVC compounds, sodium chlorate and chlorite, sodium hypochlorite, and vinyl chloride monomers. This segment's products are used as intermediates in other industrial processes to purify and treat drinking and waste water; treat and maintain swimming pool water; bleach fabrics and paper; produce solvents, detergents, and strippers; manufacture printing inks and coloring; to produce compound feed and in cooling equipment. The Intermediate Chemicals segment provides formaldehyde, glues and resins, molding powders, paraformaldehyde, pentaerythritol and dipentaerythritol, and sodium formate for manufacturing chipboards, and decorative laminates and plywoods, as well as resins, paints, and varnishes in the furniture and decoration industry; plugs and switches in the electrical components sector; and household, sanitary, and packaging materials in the textile tanning industry. The Pharmacy division engages in the production of raw materials and intermediate products from antibiotic, cholesterol-lowering, anti-ulcer, and anti-fungal agents. This segment's products include amlodipine besylate, azithromycin, clarithromycin, erythromycins, famotidine, calcium and sodium fosfomycin, fosfomycin trometamol, and fusidic acid. The company is also involved in exporting activities. Ercros, S.A. was founded in 1817 and is headquartered in Barcelona, Spain.

                    Ercros SA (ECR) Earnings & Revenues

                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Faes Farma
                    Grifols
                    LABORATORIO REIG JOFRE
                    Laboratorios Farmaceuticos Rovi
                    Repsol

                    Options Prices

                    Currently, No data available
                    ---
                    Popular Stocks